Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Abivertinib - ACEA Therapeutics

Next Previous
X
Search
Drug Profile

Abivertinib - ACEA Therapeutics

Alternative Names: A 610MA; Abivertinib maleate - ACEA Therapeutics; AC 0100; AC 0100 Maleate; AC-0010MA; ACEA-100610MA; EX-ACEA-0010MA; STI-5656

Latest Information Update: 28 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ACEA Biosciences
  • Developer ACEA Therapeutics; Guangdong Provincial Peoples Hospital; Hangzhou ACEA Pharmaceutical Research; Sorrento Therapeutics
  • Class Acrylamides; Antineoplastics; Antivirals; Fluorobenzenes; Heterocyclic compounds; Piperazines; Pyrimidines; Pyrroles; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors; Apoptosis stimulants; Epidermal growth factor receptor antagonists; Mitogen-activated protein kinase inhibitors; Raf kinase inhibitors; Ras protein inhibitors; Receptor protein-tyrosine kinase antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase II Marginal zone B-cell lymphoma; Prostate cancer
  • No development reported B-cell lymphoma; Lung cancer
  • Discontinued COVID 2019 infections

Most Recent Events

  • 28 May 2024 No recent reports of development identified for phase-I development in B-cell lymphoma(Second-line therapy or greater) in China (PO)
  • 28 May 2024 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(In the elderly, Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater, In adults) in China (PO, Capsule)
  • 28 May 2024 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater) in France (PO, Capsule)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top